FeesSafety
Pluang+

Zimmer Biomet Q3 sales rise 3.1%, stock undervalued by 23%, buy recommended amid mixed segment growth.

Company Fundamentals
21 Nov 2026, 11:01 WIB
Seeking Alpha
View Source
Bullish
Zimmer Biomet Q3 sales rise 3.1%, stock undervalued by 23%, buy recommended amid mixed segment growth.

Zimmer Biomet reported a strong third quarter with net sales increasing by 3.1%, driven by growth in hips, technology, and robotics segments, which offset weaker knee sales. The stock is currently undervalued by about 23%, with a DCF valuation suggesting a fair price of around $124 per share compared to the current $101.47. Despite challenges in the knee segment, the company’s strong cash flow and raised guidance support a buy recommendation, though investors are advised to build positions gradually as the business stabilizes. The company carries significant net debt, which could pose risks if cash flow weakens.

Zimmer Biomet's stock trades at USD 101.10 on Pluang as of Nov 21, 2026, 16:21 WIB, close to its 52-week high of USD 110.15 but well above the 52-week low of USD 79.58. The stock's 1-day change is a slight decline of 0.36%, and it carries a dividend yield of 0.95%. This positions Zimmer Biomet as a relatively stable health sector asset with a market cap of $19.20 billion, reflecting moderate investor interest compared to its recent valuation range.

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App